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Objective The aim of this analysis was to assess the association between elevated blood glucose level and mortality in
acute heart failure (AHF).
Background Elevated blood glucose has been reported to be prognostically meaningful in patients with cardiac diagnoses, such as
coronary artery disease. The short-term prognostic impact of hyperglycemia in AHF is unknown, however.
Methods In a multinational cohort of AHF, we examined the ability of blood glucose concentrations at presentation to pre-
dict all-cause mortality by 30 days. Fully adjusted models for prognosis included a previous diagnosis of diabetes
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February 26, 2013:820–9 Hyperglycemia and Outcome in Acute Heart FailureResults A total of 6,212 subjects with AHF (mean age, 72 years; 52.5% male) were studied; the median blood glucose
concentration on arrival at the hospital was 7.5 mmol/l (135 mg/dl), and 41% had a previous diagnosis of dia-
betes mellitus (DM). After 30 days, 618 patients (10%) had died. Compared with survivors, decedents had signif-
icantly higher median blood glucose concentrations (8.9 mmol/l vs. 7.4 mmol/l; p  0.0001). In the fully ad-
justed model, an elevated blood glucose level was an independent predictor of 30-day mortality in AHF (odds ratio:
2.19; 95% confidence interval: 1.69 to 2.83; p  0.001). The risk associated with an elevated blood glucose level
appeared consistent across all subgroups of patients, including patients with preserved (hazard ratio: 5.41; 95% confi-
dence interval: 2.44 to 12.0; p  0.0001) and impaired systolic function (hazard ratio: 2.37; 95% confidence interval:
1.57 to 3.59; p  0.0001). Furthermore, in reclassification analyses, elevated blood glucose added significant prog-
nostic information to clinical parameters alone (4.4% net reclassification improvement; p  0.01).
Conclusions Among patients with AHF, blood glucose concentrations at presentation are powerfully prognostic for 30-day
mortality, independent of a diagnosis of diabetes mellitus or other clinical variables. Because blood glucose is
easily modifiable, it may represent a valid target for therapeutic intervention. (J Am Coll Cardiol 2013;61:
820–9) © 2013 by the American College of Cardiology FoundationAcute heart failure (AHF) is a highly prevalent condition,
representing one of the most frequent diagnoses in the
emergency department setting (1). In addition to being
common, AHF represents a pivotal moment in the course of
the disease, characterized by a poor short-term prognosis; in
many studies, AHF has a 30-day mortality approaching
10% in patients without shock and a similarly grim inter-
mediate and longer term prognosis (2).
Factors associated with short-term mortality in AHF
typically include altered cardiovascular parameters and/or
organ dysfunction; reported variables predictive of death in
AHF include hypotension, impaired ventricular function,
altered renal function, and marked elevation of biomarkers
such as natriuretic peptides (3). However, it remains unclear
whether abnormal metabolic parameters commonly found
in serious illness are associated with an altered short-term
outcome in AHF. As an example, altered glycemic control
is common during critical illness, occurs in patients with or
without a history of diabetes mellitus (DM), and may be
associated with adverse outcome in this setting (3). In
cardiovascular diseases, abnormalities of glycemic control
have been shown to be prognostic of a higher mortality rate
in those with an acute myocardial infarction (AMI) (4–6).
However, although well established in AMI, the association
between elevated glucose concentration and increased mor-
tality in other acute cardiovascular conditions such as AHF
remains controversial (7–9). There are few studies on AHF,
and each has variable designs, with some studying only
patients without DM (10,11) and others only examining
more elderly patients (12). Moreover, the definition of
cutoff value to define hyperglycemia varies among the
studies, and the length of follow-up varied.
For these reasons and because hyperglycemia is a poten-
tially modifiable risk factor, we examined the prognostic
importance of elevated blood glucose in a large, multicenter,
international analysis of several prospective cohorts of pa-
tients with AHF. We examined the factors associated with
altered glycemic control in this setting and explored the
association between hospital admission glucose levels and
30-day mortality.Subjects and Methods
All study procedures were approved by local institutional
review boards/ethics committees.
The dataset consisted of 12 cohorts: 6 were based in
Western Europe (2 in Italy and 1 in each of the following
countries: France, Finland, Switzerland, and Spain), 2 in
Central Europe (Austria, Czech Republic), 2 in the United
States, 1 in Asia (Japan), and 1 in Africa (Tunisia) (13–21).
The principal investigators of each study submitted the
original data collected for each patient, including glucose
concentrations on admission. We defined patients as eligible
if they were identified as presenting with AHF and had
their blood glucose level measured on arrival at the emer-
gency department. All patients had AHF according to the
European Society of Cardiology guidelines (22). Both
patients with new-onset (i.e., no history) heart failure (HF)
and with decompensated chronic HF were included. For the
sake of simplicity, we used AHF to designate all studied
patients. Owing to a lack of blood glucose concentrations in
a select few, the number of patients in the other publications
may differ from those reported here. Of note, even if in all
cases data were collected prospectively, the current study is
a retrospective analysis of those data.
Clinical data, including anthropometric measures, co-
morbidities, precipitating factors, the most recent echocar-
diographic findings, clinical presentation, and medication at
baseline were recorded. A previous diagnosis of DM was
based on self-report by the patient, ongoing antidiabetic
therapy, or documentation in the patient’s medical records.
Blood glucose was measured with enzymatic methods.
Estimated glomerular filtration rate (eGFR) was calculated
from creatinine values using the Modified Diet in Renal
Disease formula (23).
Outcomes. Vital status follow-up was completed at 30
days. The endpoint of interest was death from any cause;
cardiovascular death was also evaluated.
Statistical analysis. The results are expressed as median
and first to third quartile or number and percentage. The
study outcome was defined as all-cause 30-day mortality.
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Hyperglycemia and Outcome in Acute Heart Failure February 26, 2013:820–9The log-linearity of the effect
of blood glucose was studied for
all patients and for diabetic and
nondiabetic patients separately.
The effect was found to be not
log-linear for both groups with
an inflection of the smoothing
splines at 7 mmol/l (126 mg/dl)
for nondiabetic patients and at
10 mmol/l (180 mg/dl) for dia-
betic patients (Online supple-
mentary Fig. 1). Thus, hypergly-
cemia was defined as a glucose
level of 7 mmol/l for nondia-
betic subjects and 10 mmol/l
for those with previous DM. Be-
cause patients from various coun-
tries were included, a potential
cluster effect was taken into account using a generalized
linear model with random intercept where the cluster of
interest was the country. The effect of hyperglycemia on
all-cause 30-day mortality was studied without and with
adjustment for potential confounding factors. The con-
founders included in the multiple model were age, sex,
comorbidities (history of chronic HF, history of coronary
artery disease [CAD], diabetes mellitus), systolic blood
pressure (SBP) or diastolic blood pressure, heart rate,
impaired renal function (eGFR 60 ml/min/1.73 m2) (24)
nd sodium 136 mmol/l. Moreover, the effect of hyper-
lycemia on all-cause 30-day mortality was studied in
arious pairs of subgroups (including diabetic, nondiabetic, no
nemia, anemia, de novo HF, decompensation of chronic HF,
o history of CAD, history of CAD, age 80 years, 80
ears, no history of hypertension, history of hypertension,
GFR 60 ml/min/1.73 m2, eGFR 60 ml/min/1.73 m2,
Abbreviations and
Acronyms
AHF  acute heart failure
AMI  acute myocardial
infarction
CAD  coronary artery
disease
CI  confidence interval
DM  diabetes mellitus
eGFR  estimated
glomerular filtration rate
HF  heart failure
LVEF  left ventricular
ejection fraction
SBP  systolic blood
pressure
Figure 1 Flow Chart of the Study
All acute heart failure (AHF) patients for whom 30-day outcome, blood glucose leveale, female, left ventricular ejection fraction [LVEF] 40%,
VEF 40%, LVEF 50%, LVEF 50%, median or lower
-type natriuretic peptide, B-type natriuretic peptide greater
han median, SBP 140 mm Hg, and SBP 140 mm Hg).
or each pair of subgroups, an interaction test was performed,
ndicating whether the difference of effect between the 2
ubgroups was significant.
The clinical benefit in risk prediction of adding hyper-
lycemia status to the clinical model was further assessed by
eclassification analysis, including both the net reclassifica-
ion improvement and the integrated discrimination index
25,26). Clinical variables used to build the baseline model
or mortality risk prediction were the same as those used to
djust the main analysis (i.e., age, sex, comorbidities [history
f chronic HF, CAD, and DM; SBP or diastolic blood
ressure; heart rate; eGFR 60 ml/min/1.73 m2; and
odium 136 mmol/l). In the reclassification analysis,
utoffs for low-, intermediate- and high-risk classes were
efined based on the observed overall mortality in the study
ohort. Patients were regarded as at high risk if the
redicted risk of death was approximately 2-fold the ob-
erved mortality, whereas a predicted risk around half the
bserved mortality was considered the low-risk category.
or 30-day mortality, cutoffs were defined as a predicted
isk of5%, 5% to 15%, and15% for low-, intermediate-,
nd high-risk categories.
Statistical analyses were performed using R statistical
oftware (R foundation for Statistical Computing, Vienna,
ustria). A 2-sided p value 0.05 was considered statisti-
ally significant.
esults
aseline characteristics. Among 8,213 patients with AHF
ncluded in the registry, 6,212 met the inclusion criteria for
dmission, and diabetic status were available were included in the study.l at a
823JACC Vol. 61, No. 8, 2013 Mebazaa et al.
February 26, 2013:820–9 Hyperglycemia and Outcome in Acute Heart Failurethe study and were included. The population was then
divided into to 2 groups: nonelevated blood glucose level
(n  3,391) and elevated blood glucose level (n  2,821)
according to the definition described previously (Fig. 1).
The baseline characteristics of these 6,212 studied patients
are given in Table 1.
The study subjects were typical of a population of patients
with AHF, with a mean age of nearly 72 years, a slight male
predominance (52.5%), and 41% having a history of DM.
Half of the studied patients had de novo HF (also reflected
by the clinical history and in the use of HF medications at
presentation), and the mean LVEF was 40%, indicating a
slight predominance of HF due to left ventricular systolic
dysfunction, but a substantial percentage with HF and
preserved ejection fraction. Laboratory investigations in the
study population were consistent with other studies of
AHF, with an eGFR and natriuretic peptide concentration
Baseline Characteristics of the Study SubjectsTable 1 Baseline Characteristics of the Study Subjects
Available Data,
No. (%)
Patients Studied,
(N  6,212)
Age 6,207 (99.9) 74.1 (65.0–80.8)
Male sex 6,212 (100.0) 3,258 (52.4)
Body mass index, kg/m2 3,394 (54.6) 27.1 (24.0–31.1)
Medical history
Diabetes mellitus 6,212 (100.0) 2,543 (40.9)
Chronic obstructive pulmonary
disease
5,679 (91.4) 1,161 (20.4)
Hypertension 6,064 (97.6) 4,146 (68.4)
History of heart failure 6,187 (99.6) 3,071 (49.6)
Atrial fibrillation 5,686 (91.5) 1,760 (31.0)
Coronary artery disease 6,053 (97.4) 2,946 (48.7)
Medication before admission
Beta-blocker 4,773 (76.8) 2,258 (47.3)
Angiotensin-converting enzyme
inhibitor
4,590 (73.9) 2,095 (45.6)
Angiotensin receptor blocker 4,580 (73.7) 880 (19.2)
Diuretic 4,590 (73.9) 2,661 (58.0)
Nitrate 4,567 (73.5) 1,041 (22.8)
Aspirin 4,592 (73.9) 1,903 (41.4)
Statin 4,491 (72.3) 1,335 (29.7)
Hemodynamic status at admission
Systolic blood pressure, mm Hg 6,118 (98.2) 136 (115–160)
Diastolic blood pressure, mm Hg 6,117 (98.5) 80 (69–90)
Heart rate, beats/min 6,117 (98.5) 89 (74–107)
Left ventricular ejection fraction, % 3,446 (55.5) 40 (27–55)
Laboratory test results
Hemoglobin, g/dl 5,262 (84.7) 12.9 (11.4–14.3)
Sodium, mmol/l 3,587 (57.7) 139 (136–141)
Potassium, mmol/l 6,124 (98.6) 4.2 (3.8–4.6)
Glomerular filtration rate,
ml/min/1.73 m2
6,132 (98.7) 54.2 (38.6–72.0)
Creatinine, mol/l 6,141 (98.9) 102 (79.7–137.0)
Glucose, mmol/l 6,212 (100) 7.5 (5.9–10.7)
C-reactive protein, mg/l 1,306 (21) 13 (4.5–37.0)
B-type natriuretic peptide, pg/ml 2,070 (33.3) 895.5 (444–1,710)
Values are n (%) or median (interquartile range).typical of a generally higher risk population. Characteristicsof the study population as a function of the center of origin
are detailed in Online Table 1.
Glucose concentrations at presentation. The median
blood glucose level at admission was 7.5 mmol/l (135
mg/dl). In nondiabetic patients, the blood glucose level was
elevated (7 mmol/l) in 42%, whereas in DM patients, it
was elevated (10 mmol/l) in 50%.
We first sought to identify predictors of an elevated blood
glucose level using variables available on presentation, which
are detailed in Table 2; numerous cardiometabolic risk
factors as well as prevalent CAD and HF were associated
directly or inversely with the likelihood of hyperglycemia.
Compared with a nonelevated blood glucose level, an
elevated blood glucose level was not associated with a
clinically significant alteration in hemodynamic parameters,
heart function, or renal function.
Glucose concentrations at presentation and 30-day
mortality in AHF. Overall, 618 patients (10%) died during
the 30 days of follow-up; clinical characteristics of survivors
versus decedents at 30 days are depicted in Table 3. Notably,
median glucose concentrations were higher in those dying
by 30 days compared with survivors (median [interquartile
range], 8.9 [6.7 to 13.2] vs. 7.4 [5.8 to 10.3] mmol/l,
respectively; p  0.0001). Likewise, consistent with this
association between glucose values and death, we found a
direct association between glucose concentrations on admis-
sion and 30-day mortality. When divided by the glucose
level at admission, 30-day mortality increased by 2-fold
when glycemia was between 7 and 14 mmol/l and 3-fold
when glycemia was 14 mmol/l (Fig. 2).
In a fully adjusted model for death by 30 days after
presentation with AHF, an elevated blood glucose level was
a powerfully significant predictor of risk (odds ratio: 2.19;
95% confidence interval [CI]  1.69 to 2.83; p  0.001)
(Table 4); those patients with an elevated blood glucose
level at hospital presentation had an early and sustained risk
of death at 30 days (Fig. 3).
The area under the receiver-operating characteristic curve
for an elevated blood glucose level to predict short-term
outcome was 0.61 when used alone; an elevated blood
glucose level added to a base model of clinical parameters
(those used above for adjustment), changed the area under
the curve from the clinical parameters alone (0.769 vs.
0.753, respectively; p  0.0001). The net reclassification
improvement for death at 30 days from adding elevated
blood glucose level to clinical parameters versus clinical
parameters alone was 4.4% (95% CI: 0.99 to 7.78, p 
0.016). As the net reclassification improvement is influ-
enced by the probability cut points selected, the integrated
discrimination improvement was also calculated, and an
integrated discrimination improvement of 0.011 (95% CI:
0.007 to 0.0155, p  0.001) was found.
Subgroup analyses. When examined by source of data, the
association between elevated glucose level and risk of 30-day
mortality was compellingly consistent with the exception of
outcomes in patients from Africa (Tunisia) (Fig. 4).
(
s
f
o
i
w
S
t
u
e
c
w
l
s
o
9
824 Mebazaa et al. JACC Vol. 61, No. 8, 2013
Hyperglycemia and Outcome in Acute Heart Failure February 26, 2013:820–9The risk associated with an elevated blood glucose level
appeared consistent across patients with preserved (hazard
ratio: 5.41; 95% CI; 2.44 to 12.0; p 0.0001) and impaired
hazard ratio: 2.37; 95% CI: 1.57 to 3.59; p  0.0001)
ystolic function (Table 5). When considering patients as a
unction of incident DM, interestingly, the predictive value
f elevated blood glucose appeared consistent if not stronger
n nondiabetic patients (Table 5, Fig. 5). All interactions
ere found significant in all considered subgroups.
ensitivity analyses. Sensitivity analyses (Table 6) showed
hat adjustment with the level of LVEF or plasma natri-
retic peptides on hospital admission, using a fixed-center
ffect or excluding patients with hypoglycemia (blood glu-
ose 4 mmol/l [72 mg/dl] at presentation, n  112), as
ell as excluding patients from the Czech Republic, the
argest cohort of patients) did not alter study findings. As
uch, when glucose concentrations were examined continu-
usly, we found an absolute increase in 30-day mortality of
Characteristics of Study Subjects as aFunction of Blood Gl cose Concentration on PreTable 2 Characteristics f Study Subjects aFunction of Blood Glucose Concent
Bl
N
(n
Age, yrs 74
Male sex 1,773
Body mass index, kg/m2 27.3
Medical history
Diabetes mellitus 1,276
Chronic obstructive pulmonary disease 701
Hypertension 2,215
History of heart failure 1,853
Atrial fibrillation 1,059
Coronary artery disease 1,493
Medication before admission
Beta-blocker 1,212
Angiotensin-converting enzyme inhibitor 1,093
Angiotensin receptor blocker 481
Diuretic 1,519
Nitrate 532
Aspirin 989
Statin 704
Hemodynamic status at admission
Systolic blood pressure, mm Hg 135
Diastolic blood pressure, mm Hg 80
Heart rate, beats/min 85
Left ventricular ejection fraction, % 40
Laboratory test results
Hemoglobin, g/dl 12.8
Sodium, mmol/l 139
Potassium, mmol/l 4.2
Glomerular filtration rate, ml/min/1.73 m2 55.9
Creatinine, mol/l 99
Glucose, mmol/l 6
C-reactive protein, mg/l 12
B-type natriuretic peptide, pg/ml 877
Values are median (interquartile range) or n (%).% for each 1-mmol/l (18-mg/dl) increase in blood glucose(odds ratio: 1.09; 95% CI: 1.05 to 1.12; p  0.0001). Last,
using an alternative definition of diabetes status (i.e., known
diabetes or unknown diabetes but blood glucose level at
admission 14 mmol/l [250 mg/dl]), consistent results
were found.
Discussion
Among a large multinational cohort of patients with AHF,
we found abnormal plasma glucose levels in more than half
of the studied patients and a strong prognostic importance
associated with elevated blood glucose concentrations at
presentation. The prognostic importance of elevated blood
glucose level was present in multiple subgroups analyzed,
independent of traditional covariates of risk in AHF in
adjusted analyses, and contributed to reclassification for risk
ation
on Presentation
ucose
ated
391)
Blood Glucose
Elevated
(n  2,821) p Value
0.1) 74.8 (65.6–81.2) 0.0001
1,485 (52.6) 0.78
31.2) 27 (24.2–30.9) 0.13
1,267 (44.9) 0.0001
460 (18.2) 0.00018
1,931 (70.1) 0.0086
1,218 (43.4) 0.0001
701 (27.6) 0.0001
1,453 (53) 0.0001
1,046 (46.7) 0.41
1,002 (46.3) 0.41
399 (18.5) 0.23
1,142 (52.7) 0.0001
509 (23.8) 0.15
914 (42.4) 0.23
631 (29.7) 0.98
156) 140 (115–164) 0.00019
0) 80 (68–90) 0.077
02) 93 (78–110) 0.0001
5) 40 (30–52) 0.95
14.2) 13 (11.5–14.4) 0.00011
142) 138 (135–141) 0.0001
.6) 4.2 (3.8–4.6) 0.37
73.8) 52.5 (37.5–68.7) 0.0001
34) 105 (82–140.2) 0.032
.9) 11.2 (8.4–14.4) 0.0001
3.2) 15 (5–41) 0.18
–1,680.6) 924 (473.7–1,777.5) 0.053senta
ration
ood Gl
ot Elev
 3,
(64–8
(52.3)
(23.9–
(37.6)
(22.2)
(66.9)
(54.8)
(33.7)
(45.1)
(47.9)
(45.1)
(19.9)
(62.7)
(21.9)
(40.6)
(29.7)
(115–
(70–9
(70–1
(25–5
(11.2–
(136–
(3.8–4
(39.3–
(79–1
(5.3–6
(4.1–3
(430.9stratification above a clinical model with robust perfor-
Values are median (interquartile range) or n (%).
825JACC Vol. 61, No. 8, 2013 Mebazaa et al.
February 26, 2013:820–9 Hyperglycemia and Outcome in Acute Heart Failuremance. Notably, the risk associated with an elevated blood
glucose level was seen in both patients with and without
previous diabetes mellitus.
ying by 30 Daysing Versus Dying by 30 Days
ors
594)
Nonsurvivors
(n  618) p Value
80.2) 78 (69.9–84.2) 0.0001
330 (53.4) 0.62
31.1) 26.1 (23.4–30.3) 0.00028
266 (43) 0.26
116 (20.3) 0.94
419 (68.6) 0.91
264 (42.8) 0.00034
168 (29) 0.27
334 (54.7) 0.0018
215 (42.1) 0.012
223 (44.6) 0.62
76 (15.2) 0.016
286 (57.1) 0.67
125 (25.2) 0.18
236 (47.3) 0.0049
112 (22.9) 0.00047
160) 116 (100–140) 0.0001
0) 70 (60–80) 0.0001
07) 90 (75–105) 0.99
5) 35 (25–48) 0.00046
14.3) 12.5 (10.9–14.0) 0.0001
141) 137 (134–140) 0.0001
.6) 4.3 (3.8–4.8) 0.091
73.1) 39.1 (26.0–56.5) 0.0001
132.8) 127 (96.0–186.6) 0.0001
0.3) 8.9 (6.7–13.2) 0.0001
) 32.4 (13.0–79.8) 0.0002
–1,651.3) 1,300 (679.1–2,441.6) 0.013
Multivariate Analysis of the Factors AssociatedWith 30-Day Mortality in a Fully Adjusted ModelTable 4 ultivariate Analysis of th Fac ors AssociatedWith 30-Day Mortality in a Fully Adjusted Model
OR (95% CI) p Value
Elevated blood glucose 2.19 (1.69–2.83) 0.0001
Estimated glomerular filtration rate
60 ml/min/1.73 m2
1.82 (1.46–2.28) 0.0001
Sodium 136 mmol/l 1.73 (1.41–2.12) 0.0001
Age (for 10 yrs) 1.54 (1.40–1.70) 0.0001
Previous diabetes mellitus 1.42 (1.05–1.91) 0.0225
Sex 1.16 (0.96–1.41) 0.121
Heart rate (for each 10 beats/min) 1.01 (0.98–1.05) 0.541
Diastolic blood pressure (for each 10 mm Hg) 0.89 (0.82–0.96) 0.0041
Previous coronary artery disease 0.88 (0.72–1.07) 0.21
Previous heart failure 0.77 (0.63–0.93) 0.0084
Systolic blood pressure (for each 20 mm Hg) 0.73 (0.67–0.80) 0.0001Characteristics of Study Subjects Surviving Versus DTable 3 Characteristics of Study Subjects Surviv
Surviv
(n  5,
Age, yrs 73.8 (64.4–
Male sex 2,928 (52.3)
Body mass index, kg/m2 27.2 (24.1–
Medical history
Diabetes mellitus 2,277 (40.7)
Chronic obstructive pulmonary disease 1,045 (20.5)
Hypertension 3,727 (68.3)
History of heart failure 2,807 (50.4)
Atrial fibrillation 1,592 (31.2)
Coronary artery disease 2,612 (48)
Medication before admission
Beta-blocker 2,043 (47.9)
Angiotensin-converting enzyme inhibitor 1,872 (45.8)
Angiotensin receptor blocker 804 (19.7)
Diuretic 2,375 (58.1)
Nitrate 916 (22.5)
Aspirin 1,667 (40.7)
Statin 1,223 (30.6)
Hemodynamic status at admission
Systolic blood pressure, mm Hg 140 (120–
Diastolic blood pressure, mm Hg 80 (70–9
Heart rate, beats/min 88 (73–1
Left ventricular ejection fraction, % 40 (28–5
Laboratory test results
Hemoglobin, g/dl 12.9 (11.4–
Sodium, mmol/l 139 (136–
Potassium, mmol/l 4.2 (3.8–4
Glomerular filtration rate, ml/min/1.73 m2 55.5 (40.2–
Creatinine, mol/l 99 (79.6–
Glycemia, mmol/l 7.4 (5.8–1
C-reactive protein, mg/l 12 (4–33
B-type natriuretic peptide, pg/ml 878.2 (434.2Figure 2 30-Day Mortality Rates According
to the Level of Glucose at Admission
Blood glucose level at admission 14 mmol/l was associated with a 3-fold
higher risk of death compared with patient with a normal glycemia level. CI 
confidence interval; OR  odds ratio. Elevated blood glucose showed the highest odds ratio.
CI  confidence interval; OR  odds ratio.
fi
p
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a number of medical states such as AMI (27), stroke (28),
pulmonary diseases (29), and critical illness (30–32) is well
recognized. Indeed, multiple clinical practice guidelines
recommend careful monitoring of blood glucose for this
reason, with some recommending treatment with a goal to
improve nonendocrinological outcomes (33), despite mixed
results regarding this approach (34). However, risks related
to glucose concentrations in the context of AHF are not
well established. For example, 1 very large study of elderly
and medically complex patients with AHF found no link
between blood glucose levels and outcome (9), whereas
other smaller studies of generally younger and less medically
Figure 3 Cumulative Hazard for Death Associated With
Hyperglycemia on Arrival at Hospital With AHF
Mortality was higher within few days in acute heart failure patients
with elevated blood glucose levels.
Figure 4
30-Day Mortality Odds Ratio for Death Associated
With Hyperglycemia: Comparison Among
Various Continents
There are important variations in the risk of death among the continents.
Although elevated blood glucose level was independently associated with
30-day mortality in North America, in Central and Western Europe, the associa-
tion was not significant in Africa and in Asia.complex patients did find glucose concentrations associated
with adverse outcomes, particularly while in the hospital or
soon after discharge (7,8,35). In our large international
cohort of subjects with a profile rather representative of a
real-world sample of AHF patients from a demographics
and medical profile perspective (36,37), we found a clear and
significant adverse prognostic impact related to hyperglyce-
mia, a risk that was present in patients with or without
incident DM and across a wide range of ethnicities and left
ventricular function.
It is not entirely clear whether elevated blood glucose
level in AHF is a marker for risk or a mediator of adverse
outcomes. In the present study, hyperglycemia did not seem
overtly associated with signs of altered hemodynamic, heart,
or renal function. Nonetheless, severe systemic stress may
lead to higher glucose levels due to effects of the sympathetic
nervous system or from excessive release of adrenally derived
hormones such as cortisol (32,38), and mechanistically,
elevated blood glucose has been repeatedly shown to be
30-Day Mortality Hazard Ratioin Various Clinically Relevant SubgroupsTable 5 30-Da Mortality Haza d Ratioin Various Clinically Relevant Subgroups
Risk of Death in Patients
With Elevated Blood
Glucose
p Value
InteractionNo. OR (95% CI)
Diabetic 2,543 2.18 (1.67–2.83)  0.0001
Nondiabetic 3,669 1.65 (1.23–2.22)
No anemia 3,059 2.87 (1.95–4.23)  0.0001
Anemia 2,203 1.61 (1.09–2.38)
De novo HF 3,116 2.23 (1.58–3.16) 0.005
Decompensation of chronic HF 3,071 2.10 (1.42–3.11)
No history of CAD 3,107 2.27 (1.58–3.25)  0.0001
History of CAD 2,946 2.1 (1.45–3.06)
Age, yrs
80 4,537 2.34 (1.67–3.28) 0.0001
80 1,670 2.04 (1.38–3.03)
No history of hypertension 1,918 2.12 (1.40–3.20) 0.005
History of hypertension 4,146 2.19 (1.58–3.06)
eGFR, ml/min/1.73 m2
60 2,516 2.36 (1.4–3.98) 0.0001
60 3,616 2.12 (1.58–2.86)
Male 3,258 2.53 (1.72–3.71)  0.0001
Female 2,954 2.02 (1.42–2.86)
LVEF, %
40 1,764 3.30 (1.92–5.67)  0.0001
40 1,682 2.54 (1.55–4.18)
50 1,156 5.41 (2.44–12)  0.0001
50 2,290 2.37 (1.57–3.59)
BNP
Median or lower* 1,035 1.63 (0.79–3.38) 0.0001
Greater than median* 1,035 2.54 (1.30–4.96)
SBP, mm Hg
140 3,613 1.90 (1.42–2.54) 0.0001
140 2,505 3.25 (1.78–5.93)
BNP  B-type natriuretic peptide; CAD  coronary artery disease; eGFR  estimated glomerular
ltration rate; HF  heart failure; LVEF  left ventricular ejection fraction; SBP  systolic blood
ressure; other abbreviations as in Table 4.directly deleterious to cardiac performance. Chronically
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February 26, 2013:820–9 Hyperglycemia and Outcome in Acute Heart Failureelevated glucose levels (as evidenced by an elevated HbA1c)
ave been shown to be associated with myocardial injury
reflected in elevated, highly sensitive troponin concentra-
ions) in patients free of HF (39), whereas intensive glyce-
ic control may reduce cardiovascular events likely through
oronary and noncoronary mechanisms (40). Furthermore,
igher glucose levels may lead to an abnormally elevated
oncentration of circulating free fatty acids, increased myo-
ardial uptake of free fatty acids (which in turn may promote
rrhythmogenesis) (41), and decreased myocardial uptake of
lucose (42). Hyperglycemia may also directly promote a
umber of negative effects at the myocyte level, including
eranged calcium metabolism (23), apoptosis, and progres-
ive remodeling. This latter observation may be due to the
act that elevated glucose increases concentrations of nuclear
actor B, with consequent up-regulation of matrix metal-
oproteinases (43). Indeed, elevated glucose levels in the
ontext of AMI clinically predict the onset of symptomatic
F (44). As well, hyperglycemia may lead to other untow-
rd effects on the cardiovascular system, including endothe-
ial dysfunction, vascular inflammation, and accelerated
therogenesis (45). Thus, one can envision numerous rea-
ons why hyperglycemia might lead to an adverse outcome
n patients with AHF; in our cohort, the early and substan-
Figure 5 Risk of Death Associated With Elevated Blood Glucos
Function of the Presence or Absence of Diabetes Mel
Although the risk of death seemed higher for acute heart failure patients with prev
elevated blood glucose level and 30-day mortality existed in both patients without
Sensitivity AnalysesTable 6 Sensitivity Analyses
Without Central Europe 1.85 (1.32–2.60)
Fixed cluster effect 2.34 (1.82–3.01)
Without patient with hypoglycemia 2.28 (1.76–2.96)
After adjustment of LVEF* 2.83 (1.97–4.07)
After adjustment of BNP* 2.00 (1.23–3.27)
Using alternative definition of diabetes† 2.07 (1.59–2.70)
Values are adjusted odds ratios (95% confidence interval).
*In addition of the other variables already used for adjustment.
†Diabetes was defined here either as known diabetes at admission or unknown diabetes buts
glycemia 14 mmol/l (250 mg/dl) at admission.
Abbreviations as in Tables 4 and 5.ial risk associated with elevated glucose concentrations
rgues most compellingly for a direct myocardial effect,
elated to either reduced pump function or arrhythmia
romotion. Considerably more data are needed to answer
hether hyperglycemia is a marker or mediator, but our
ompelling data suggest the latter rather than the former.
The clinical implications of our study are numerous.
irst, because blood glucose is widely measured, easily
nterpreted, and inexpensive to measure, its use for risk
ssessment in AHF is worthy of consideration. Second, our
ata suggest that stress-induced impaired glucose tolerance
nd/or occult diabetes mellitus among patients with AHF is
ommon and deserves further study, especially with respect
o efforts at follow-up care and longer term management.
linicians should recognize the fact that in-hospital hyper-
lycemia likely predicts future issues with glycemic control
nd monitor and manage accordingly. Last, because 30-day
utcomes are a very relevant endpoint in AHF and driven
argely by early treatment decision making, the robust
ssociations between serum glucose levels and fatal out-
omes in this population immediately conjure up the need
or consideration of a treatment trial comparing aggressive
nd permissive glycemic management in patients presenting
ith AHF. Given the tight associations between hypergly-
emia and myocardial performance discussed earlier, it is
easonable to consider not only expected superior clinical
utcomes from aggressive glycemic control, but also im-
roved myocardial performance and remodeling.
The differences observed among the continents and
specially the lack of association in Asia and Africa are
ntriguing. Several explanations could be considered. First,
hese 2 continents were associated with the lowest sample
ize; thus, the results are probably underpowered, and it
eems difficult to draw a conclusion. Second, ethnic blood
lucose variations have recently been described (46). In this
el as a
on Admission
iabetes mellitus compared with others, the association between
ith this comorbidity.e Lev
litus
ious d
and wtudy, the authors found that South Asian individuals had
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Hyperglycemia and Outcome in Acute Heart Failure February 26, 2013:820–9higher blood glucose levels, even after taking into account
risk factors that influence sugar levels, compared with white
European individuals. Whether this reflects an ethnic or
racial resistance to the effects of hyperglycemia or merely a
difference in clinical management after presentation remains
unclear, and more data regarding this finding are needed.
Study limitations. Limitations include the fact that we
lack data regarding HbA1c at admission and serial measure-
ent of glucose during the hospital stay and whether this
rovides superior risk stratification beyond presenting values
f blood glucose. We similarly lack data regarding in-
ospital treatment of DM and/or hyperglycemia. Despite
hese facts, the powerful association between presenting
lucose level and risk of death is unmistakable and implies
he need for further study. Future analyses should consider
erial measurements of blood glucose after presentation,
ith an effort to define the trajectory of hyperglycemia in
hose destined for an adverse outcome. The question of
hether patients with hyperglycemia in the nondiabetic
roup were in fact underdiagnosed diabetic patients and
hether this potential misclassification would have altered
nal results remained unanswered. However, this is unlikely
o be true because we showed that hyperglycemia is consis-
ently associated with poor short-term outcome in all
tudied subgroups including in the subgroup of diabetic
atients and in all sensitivity analyses.
onclusions
n this large multinational cohort of patients with AHF, we
howed that an elevated blood glucose level is common and
s a powerful risk marker, predicting death within 30 days.
ur results are consistent with basic and clinical science
ata linking an elevated blood glucose level with myocardial
njury, impaired myocardial performance, arrhythmia, and
isk of ventricular remodeling. Furthers studies are needed
o understand more thoroughly the physiopathology of
yperglycemia in AHF.
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